BIOMAT Database Logo BIOMAT Database Logo

Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k. 2004

Francis X Tavares, and Virginia Boncek, and David N Deaton, and Anne M Hassell, and Stacey T Long, and Aaron B Miller, and Alan A Payne, and Larry R Miller, and Lisa M Shewchuk, and Kevin Wells-Knecht, and Derril H Willard, and Lois L Wright, and Hui-Qiang Zhou
Department of Medicinal Chemistry, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA. fxt66911@gsk.com

Osteoclast-mediated bone matrix resorption has been attributed to cathepsin K, a cysteine protease of the papain family that is abundantly and selectively expressed in osteoclast. Inhibition of cathepsin K could potentially be an effective method to prevent osteoporosis. Structure-activity studies on a series of reversible ketoamides based inhibitors of cathepsin K have led to identification of potent and selective compounds. Crystallographic studies have given insights into the mode of binding of these inhibitors. A series of ketoamides with varying P1 moieties were first synthesized to find an optimum group that would fit into the S1 subsite of the cysteine protease, cathepsin K. With a desired P1 group in place a variety of heterocyclic analogues in the P' region were synthesized to study their steric and electronic effects. In the process of exploring these P' heterocyclic variations, excellent selectivity was gained over other highly homologous cysteine proteases, including cathepsins L, S, and V. The favorable pharmacokinetic properties of some of these cathepsin K inhibitors in rats make them suitable for evaluation in rodent osteoporosis models. A representative cathepsin K inhibitor was shown to attenuate PTH-stimulated hypercalcemia in the TPTX rat model. These inhibitors provide a viable lead series in the discovery of new therapies for the prevention and treatment of osteoporosis

UI MeSH Term Description Entries
D007659 Ketones Organic compounds containing a carbonyl group Ketone
D008297 Male Males
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D010024 Osteoporosis Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis. Age-Related Osteoporosis,Bone Loss, Age-Related,Osteoporosis, Age-Related,Osteoporosis, Post-Traumatic,Osteoporosis, Senile,Senile Osteoporosis,Osteoporosis, Involutional,Age Related Osteoporosis,Age-Related Bone Loss,Age-Related Bone Losses,Age-Related Osteoporoses,Bone Loss, Age Related,Bone Losses, Age-Related,Osteoporoses,Osteoporoses, Age-Related,Osteoporoses, Senile,Osteoporosis, Age Related,Osteoporosis, Post Traumatic,Post-Traumatic Osteoporoses,Post-Traumatic Osteoporosis,Senile Osteoporoses
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002118 Calcium A basic element found in nearly all tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. Coagulation Factor IV,Factor IV,Blood Coagulation Factor IV,Calcium-40,Calcium 40,Factor IV, Coagulation
D002403 Cathepsins A group of lysosomal proteinases or endopeptidases found in aqueous extracts of a variety of animal tissues. They function optimally within an acidic pH range. The cathepsins occur as a variety of enzyme subtypes including SERINE PROTEASES; ASPARTIC PROTEINASES; and CYSTEINE PROTEASES. Cathepsin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000577 Amides Organic compounds containing the -CO-NH2 radical. Amides are derived from acids by replacement of -OH by -NH2 or from ammonia by the replacement of H by an acyl group. (From Grant & Hackh's Chemical Dictionary, 5th ed) Amide

Related Publications

Francis X Tavares, and Virginia Boncek, and David N Deaton, and Anne M Hassell, and Stacey T Long, and Aaron B Miller, and Alan A Payne, and Larry R Miller, and Lisa M Shewchuk, and Kevin Wells-Knecht, and Derril H Willard, and Lois L Wright, and Hui-Qiang Zhou
Potent and selective ketoamide-based inhibitors of cysteine protease, cathepsin K.
October 2004, Journal of medicinal chemistry,
Francis X Tavares, and Virginia Boncek, and David N Deaton, and Anne M Hassell, and Stacey T Long, and Aaron B Miller, and Alan A Payne, and Larry R Miller, and Lisa M Shewchuk, and Kevin Wells-Knecht, and Derril H Willard, and Lois L Wright, and Hui-Qiang Zhou
Potent dipeptidylketone inhibitors of the cysteine protease cathepsin K.
April 1999, Bioorganic & medicinal chemistry,
Francis X Tavares, and Virginia Boncek, and David N Deaton, and Anne M Hassell, and Stacey T Long, and Aaron B Miller, and Alan A Payne, and Larry R Miller, and Lisa M Shewchuk, and Kevin Wells-Knecht, and Derril H Willard, and Lois L Wright, and Hui-Qiang Zhou
Orally bioavailable cathepsin K inhibitors with pyrrolopyrimidine scaffold.
January 2010, Current topics in medicinal chemistry,
Francis X Tavares, and Virginia Boncek, and David N Deaton, and Anne M Hassell, and Stacey T Long, and Aaron B Miller, and Alan A Payne, and Larry R Miller, and Lisa M Shewchuk, and Kevin Wells-Knecht, and Derril H Willard, and Lois L Wright, and Hui-Qiang Zhou
Acyclic, orally bioavailable ketone-based cathepsin K inhibitors.
January 2007, Bioorganic & medicinal chemistry letters,
Francis X Tavares, and Virginia Boncek, and David N Deaton, and Anne M Hassell, and Stacey T Long, and Aaron B Miller, and Alan A Payne, and Larry R Miller, and Lisa M Shewchuk, and Kevin Wells-Knecht, and Derril H Willard, and Lois L Wright, and Hui-Qiang Zhou
Structure-Based Design of Potent, Selective, and Orally Bioavailable VPS34 Kinase Inhibitors.
September 2022, Journal of medicinal chemistry,
Francis X Tavares, and Virginia Boncek, and David N Deaton, and Anne M Hassell, and Stacey T Long, and Aaron B Miller, and Alan A Payne, and Larry R Miller, and Lisa M Shewchuk, and Kevin Wells-Knecht, and Derril H Willard, and Lois L Wright, and Hui-Qiang Zhou
Potent and selective cathepsin K inhibitors.
October 2006, Bioorganic & medicinal chemistry,
Francis X Tavares, and Virginia Boncek, and David N Deaton, and Anne M Hassell, and Stacey T Long, and Aaron B Miller, and Alan A Payne, and Larry R Miller, and Lisa M Shewchuk, and Kevin Wells-Knecht, and Derril H Willard, and Lois L Wright, and Hui-Qiang Zhou
Orally bioavailable small molecule ketoamide-based inhibitors of cathepsin K.
May 2004, Bioorganic & medicinal chemistry letters,
Francis X Tavares, and Virginia Boncek, and David N Deaton, and Anne M Hassell, and Stacey T Long, and Aaron B Miller, and Alan A Payne, and Larry R Miller, and Lisa M Shewchuk, and Kevin Wells-Knecht, and Derril H Willard, and Lois L Wright, and Hui-Qiang Zhou
The identification of potent, selective, and bioavailable cathepsin S inhibitors.
September 2007, Bioorganic & medicinal chemistry letters,
Francis X Tavares, and Virginia Boncek, and David N Deaton, and Anne M Hassell, and Stacey T Long, and Aaron B Miller, and Alan A Payne, and Larry R Miller, and Lisa M Shewchuk, and Kevin Wells-Knecht, and Derril H Willard, and Lois L Wright, and Hui-Qiang Zhou
Protein structure-based design of potent orally bioavailable, nonpeptide inhibitors of human immunodeficiency virus protease.
April 1995, Proceedings of the National Academy of Sciences of the United States of America,
Francis X Tavares, and Virginia Boncek, and David N Deaton, and Anne M Hassell, and Stacey T Long, and Aaron B Miller, and Alan A Payne, and Larry R Miller, and Lisa M Shewchuk, and Kevin Wells-Knecht, and Derril H Willard, and Lois L Wright, and Hui-Qiang Zhou
Novel, potent, selective, and orally bioavailable human betaII-tryptase inhibitors.
August 2006, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!